ARK Investment Management Reduces $27M in 10x Genomics, Inc. ($TXG)

ARK Investment Management trimmed its position in 10x Genomics by 7.5% in the latest 13F filing.

Written by Trueearnings · Published Jun 14, 2026, 4:53 AM EDT

Key Points

ARK Investment Management reduced its stake in 10x Genomics by 950,052 shares, now holding 11,717,317 shares.
10x Genomics trades on NasdaqGS with a market cap of $3.66 billion and a forward P/E of 144.2.
Recent insider buying involved multiple executives acquiring 8,829 shares each on June 4, 2026.

In its latest 13F filing with the SEC, ARK Investment Management reported trimming its position in 10x Genomics, Inc. (NasdaqGS: TXG). The fund reduced its holdings by 950,052 shares, a 7.5% decrease, bringing its total to 11,717,317 shares valued at approximately $337.9 million as of the reporting period.

What Changed in ARK Investment Management's 10x Genomics Position

ARK Investment Management cut back its investment in 10x Genomics, reducing its holdings from 12,667,369 shares to 11,717,317 shares. The reduction of 950,052 shares represents a 7.5% decrease in their position, with the stake now valued at roughly $337.9 million.

Other Institutional Activity in 10x Genomics

Several other funds have also adjusted their positions in 10x Genomics. FMR LLC increased its holdings significantly, adding 5,823,490 shares to end with 17,740,972 shares worth about $376.6 million. BlackRock, Inc. made a smaller adjustment, adding 65,451 shares, bringing its total to 10,079,913 shares valued at $214.0 million. Meanwhile, Quantinno Capital Management LP boosted its position by 744,558 shares, ending with 5,411,761 shares valued at $114.9 million.

10x Genomics Stock Snapshot

Shares of 10x Genomics (NasdaqGS: TXG) recently traded near $28.84. The company has a market cap of approximately $3.66 billion and a forward P/E ratio of 144.2, indicating high expectations for future earnings. The stock's beta, a measure of volatility, stands at 2.114. Over the past year, the stock has ranged from a low of $10.17 to a high of $35.645, with a 50-day moving average of $24.49 and a 200-day moving average of $18.73.

Recent Earnings

10x Genomics reported revenue of $638.8 million, though it experienced a slight revenue decline of 2.6%. The company posted a negative net margin of 3.5% and a return on equity of -3.0%, highlighting ongoing profitability challenges. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at 10x Genomics, Inc.

On June 4, 2026, several insiders at 10x Genomics made purchases. Mateo Alan, Sridhar Kosaraju, Kimberly Popovits, Sarah Teichmann, Shehnaaz Suliman, and John Stuelpnagel each acquired 8,829 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

Analysts have maintained their ratings on 10x Genomics with various price targets. On May 12, 2026, Morgan Stanley and JP Morgan both maintained a "hold" rating, with price targets of $22 and $20, respectively. Canaccord Genuity earlier on April 20, 2026, maintained a "buy" rating with a target of $32. The consensus among analysts remains a "buy," with a mean target price of $25.77 based on 13 analyst opinions.

About 10x Genomics

10x Genomics, Inc., headquartered in Pleasanton, California, is a healthcare company specializing in advanced tools for analyzing biological systems. It offers the Chromium platform for single-cell analysis and the Visium platform for spatial analysis. The company serves a diverse range of customers, including academic, government, and biopharmaceutical institutions. Led by CEO Dr. Serge Saxonov, 10x Genomics employs approximately 1,178 people.

Bottom Line

ARK Investment Management's recent reduction in its 10x Genomics holdings is part of a broader trend among institutional investors. These filings offer a glimpse into past fund strategies and do not necessarily reflect current positions. Investors often use such data to gauge institutional confidence and stock performance trends.